Search

Your search keyword '"Stroes, Erik S"' showing total 1,158 results

Search Constraints

Start Over You searched for: Author "Stroes, Erik S" Remove constraint Author: "Stroes, Erik S"
1,158 results on '"Stroes, Erik S"'

Search Results

4. Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study

6. Covered Information Disentanglement: Model Transparency via Unbiased Permutation Importance

8. Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis

9. Transcriptomic-based clustering of human atherosclerotic plaques identifies subgroups with different underlying biology and clinical presentation

13. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

14. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network

16. Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial.

17. First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin.

18. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

19. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

21. Manifold Mixing for Stacked Regularization

23. Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis.

24. Moving from lipids to leukocytes: inflammation and immune cells in atherosclerosis.

25. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

26. Plasma C-reactive protein is associated with a pro-inflammatory and adverse plaque phenotype

28. Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial

29. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

31. Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia

32. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.

34. Garadacimab for the prevention of hereditary angioedema attacks: a plain language summary of the VANGUARD study

37. Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease

40. ANGPTL3 (Angiopoietin‐Like 3) Preferentially Resides on High‐Density Lipoprotein in the Human Circulation, Affecting Its Activity

41. Concordance of a High Lipoprotein(a) Concentration Among Relatives

45. Treatment with Anaerobutyricum soehngenii: a pilot study of safety and dose–response effects on glucose metabolism in human subjects with metabolic syndrome

50. Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates

Catalog

Books, media, physical & digital resources